DAKLIZUMAB (Daclizumab).

     Synonym : Zenapaks, Zenapax.

     Recombinant monoklonalnoe antibodies.

     A receptor antagonist interleykina-2, prevents them caused lymphocyte activation and immune response in violation of antigen.

     Applied (in combination with cyclosporine and glyukokortikosteroidami) for the prevention of acute reactions tissue incompatibility with renal transplantation.

     Enter intravenously (over 15 minutes) in the dose of 1 mg / kg, beginning no earlier than 24 hours prior to transplant kidneys, one every two weeks; In the course of five injections (peak drug concentrations in the blood following the 5 th dose T ? - 11-38 days).

     Possible side effects : pain in the chest, increased body temperature, tachycardia, tremor, nausea, vomiting, etc.

     Product : 0.5% concentrate for infusions in bottles to 5 ml.

Materials allowed to copy only with the active hyperlink to the handbook of medicines